Trastuzumab
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is given by slow injection into a vein and injection just under the skin.
Trastuzumab Fab region (cyan) binding HER2/neu (gold) | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | HER2/neu |
Clinical data | |
Trade names | Herceptin, Herceptin SC, others |
Biosimilars | trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, Herzuma, Herwenda, Kanjinti, Ogivri, Ontruzant, Trastucip, Trazimera, Tuzucip, Zercepac |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous, subcutaneous |
Drug class | Antineoplastic agent |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Unknown, possibly reticuloendothelial system |
Elimination half-life | 2-12 days |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.224.377 |
Chemical and physical data | |
Formula | C6470H10012N1726O2013S42 |
Molar mass | 145531.86 g·mol−1 |
(what is this?) (verify) |
Common side effects include fever, infection, cough, headache, trouble sleeping, and rash. Other severe side effects include heart failure, allergic reactions, and lung disease. Use during pregnancy may harm the baby. Trastuzumab works by binding to the HER2 receptor and slowing down cell replication.
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000. It is on the World Health Organization's List of Essential Medicines.